Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.68 |
| ▸ | HTR3B | O95264 | 3/20 | 0.68 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.68 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916740 | 0.83 | HTR3A (0.68) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3916736 | 0.81 | HTR3A (0.66) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| [11C]Phenethylguanidine SCHEMBL837645 | 0.80 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL14763877 | 0.79 | HTR3A (0.63) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL7635935 | 0.77 | GRIN1 (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3929410 | 0.76 | HTR3E (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3925719 | 0.74 | ALOX15 (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8079404 | 0.74 | TSHR (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2914010 | 0.73 | GFER (0.77) | GFERTSHRMAOBTDP1MAPT | |
| SCHEMBL12110702 | 0.73 | GFER (0.77) | GFERTSHRMAOBTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461811-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M Innovative Properties Co. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10239828-B2 | Process for preparing guanidino-functional monomers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3010883-B1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES CO (US) | 2019-02-20 | — | — | EP | disclosed |
| CN-105308021-B | It is used to prepare the method for guanidine radicals functionalized monomer | 3M创新有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-20170183299-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-06-29 | — | — | US | disclosed |
| US-9670149-B2 | Process for preparing guanidino-functional monomers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3010883-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M Innovative Properties Company (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2016-04-07 | — | — | US | disclosed |
| WO-2014204763-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-12-24 | — | — | WO | disclosed |
| EP-0914333-B1 | PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946596-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096802-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | GMPS, GUCY1B2, GUCY1A1 | HTR3A 1499/4885HTR3E 3723/4885HTR3B 1713/4885 |
| US-10239828-B2 | Process for preparing guanidino-functional monomers | GMPS, GUCY1B2, GUCY1A1 | HTR3A 1499/4885HTR3E 3723/4885HTR3B 1713/4885 |
| US-20170183299-A1 | PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS | GMPS, GUCY1B2, GUCY1A1 | HTR3A 1499/4885HTR3E 3723/4885HTR3B 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.